Surgical Margin Status of Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Radical Intent: Risk Factors for the Survival Impact of Positive Margins

CHUN-CHI LAI1*, SHANG-YU WANG2,3*, CHIEN-HUNG LIAO2, JUN-TE HSU1, KUN-CHUN CHIANG4, TA-SEN YEH1, TSANN-LONG HWANG1 and CHUN-NAN YEH1

1Division of General Surgery, and 2Division of Trauma and Emergency Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.; 3Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C.; 4Division of General Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.

Abstract. Background: For pancreatic ductal adenocarcinoma (PDAC), surgical margin status is an important pathological factor for evaluating surgical adequacy. In this study, we attempted to investigate predictive factors for the survival impact of positive surgical margins. Materials and Methods: From February 2004 to December 2013, 204 patients were diagnosed with PDAC and underwent surgery with radical intent; 189 patients fulfilled our selection criteria and were enrolled for analysis. Results: For the 189 enrolled patients with PDAC, we found male predominance (112/189, 59%) and a median age of 64 years; most patients were diagnosed with stage IIB disease (n=115, 61%). The positive surgical margin rate was 21% (n=40). Carbohydrate antigen 19-9 (CA19-9) level higher than 246 U/ml (odds ratio (OR)=2.318; 95% confidence interval (CI)=1.037-5.181 p=0.040) and lesion location in the uncinate process (OR=2.996; 95% CI=1.232-7.284 p=0.015) were the only two independent risk factors for positive surgical margins. Positive retroperitoneal soft-tissue margins were the most frequently observed (24/40, 60%). Overall, positive surgical margins had no survival impact in the 189 patients with PDAC who underwent surgery; however, positive surgical margins had an unfavorable survival impact on patients with stage IIA PDAC who underwent surgery. Conclusion: Retroperitoneal soft-tissue was the most common site for positive surgical margins. Additionally, surgical margin positivity was more likely for tumors located in the uncinate process than for other tumors. Positive surgical margins had an unfavorable survival impact on patients with stage IIA PDAC who underwent surgery.

Pancreatic ductal adenocarcinoma (PDAC) is a dismal condition with poor prognosis. The 5-year overall survival for PDAC may be as low as 1.3% (1). This poor outcome is attributable to advanced disease at diagnosis and inefficient treatment modalities. However, surgical resection remains the mainstream treatment for both primary tumor excision and precise staging for adjuvant treatment. Unfortunately, only 15-20% patients present with resectable disease at diagnosis (2, 3). For resectable PDAC, 5-year overall survival may be improved to up to 18% (4). For resectable PDAC, surgical margin status is an important pathological factor for evaluating surgical adequacy. However, the impact of this status on long-term clinical outcome remains debatable (5, 6). In this study, we attempted to investigate predictive factors for positive surgical margins after surgery with radical intent and the survival impact of surgical margin status.

Materials and Methods

From February 2004 to December 2013, 204 patients were diagnosed with PDAC and underwent surgery with radical intent. Eleven patients were excluded due to involvement of the superior mesentery artery or occult distant metastasis revealed after laparotomy. Four patients with surgical mortality (4/204, 1.96%, hospital mortality within 30 days after surgery) were also excluded. Therefore, 189 patients were enrolled for analysis (Figure 1). Medical records were reviewed and analyzed; the assessed items included clinical, laboratory, and pathological findings. Conventional Whipple’s
operation, pylorus-preserving pancreaticoduodenectomy, subtotal or distal pancreatectomy, or total pancreatectomy was performed as appropriate given the location of the lesion. Pathological results were reviewed. The location of the lesion was categorized into four major groups: head and neck; body; tail; and uncinate process. The investigated margins included pancreatic margins, the common bile duct margin, the duodenal margin, and the retroperitoneal soft-tissue margin. In our study, positive margins were defined either macroscopically or microscopically. A margin clearance of more than 0 mm was used to define R0 resection. Disease stage was determined based on the seventh edition of the American Joint Committee of Cancer (AJCC) staging manual (7).

**Risk factors for positive surgical margin.** To explore risk factors for positive surgical margins, the 189 patients were categorized into two groups: negative margins (n=149) and positive margins (n=40). Age, gender, laboratory data, tumor markers, disease stage, macroscopic pathological factors, and microscopic pathological factors were compared between these groups. Factors revealed to be significant by univariate analysis were further assessed via multivariate analysis.

**Survival impact.** Survival analysis was conducted for both groups based on individual margin status. Subgroup analyses based on disease stage were also performed. In addition to univariate analysis, multivariate Cox proportional hazard analysis was also conducted to eliminate confounding effects produced by other factors.

**Statistical procedures.** The threshold for statistical significance was defined as \( p < 0.05 \). Continuous variables were analyzed using the independent Student’s \( t \)-test, whereas categorical variables were assessed using the Pearson chi-square test. Multivariate analysis was performed via logistic regression. Survival analysis was conducted using both a log-rank test (univariate) and a Cox hazards model (multivariate). SPSS v.21 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. A value of \( p < 0.05 \) was considered statistically significant.

**Results**

Table I summarizes the demographic data, disease status, surgical method, and margin status for the study cohort. Male predominance (n=112, 59%) and a median age of 64 years were observed. Most lesions were located in the head and neck (n=132, 70%), and most of the surgical procedures were pancreaticoduodenectomies, either conventional (n=102, 54%) or pylorus-preserving (n=62, 33%). Most patients in the study cohort were diagnosed with stage IIB PDAC (n=115, 61%). The rate of surgical margin positivity was 21% (n=40).

Univariate analysis revealed that high carbohydrate antigen 19-9 (CA19-9) level and lesion location in the uncinate process were significantly associated with positive surgical margin (Table II). Subsequent multivariate analysis demonstrated that both factors [specifically, CA19-9 level higher than 246 U/ml (OR=2.318; 95% CI=1.037-5.181 \( p=0.040 \)] and lesion location in the uncinate process (OR=2.996; 95% CI=1.232-7.284 \( p=0.015 \)) were independently associated with positive surgical margins.

Retroperitoneal soft-tissue margins were the most commonly observed positive surgical margins (n=24; 24/40, 60%). When the site of the primary tumor was considered (Table III), the risk of a positive retroperitoneal soft-tissue margin was higher for patients with tumors in the uncinate process (92%) than for those with tumor in other locations (50%).

Patients with negative surgical margins (n=149) had overall survival similar to that of patients with positive surgical margins (n=40) (Figure 2). Because of the small number of patients with stage IA or stage IB PDAC, only analyses of stage IIA (n=57) and stage IIB (n=114) were performed using the Cox proportional hazards model. The factors used for analysis included age, gender, tumor location, CA19-9 level, tumor size, histology, mitotic count, lymph node ratio, lymphatic invasion, vascular invasion, peri-neural invasion, margin status, and chemotherapy application. Negative surgical margins, normal CA19-9 level, and well-differentiated histology were the three independent factors that favored survival for those with stage IIA disease (Table IV). No independent factors that significantly affected survival were identified for those with stage IIB disease (Table V).

| Characteristic | Value |
|---------------|-------|
| Gender, n (%) |       |
| Male          | 112 (59%) |
| Female        | 77 (41%)  |
| Age, years    |       |
| Median (IQR)  | 64 (56-73) |
| Stage, n (%)  |       |
| IA            | 2 (1%)   |
| IB            | 15 (8%)  |
| IIA           | 57 (30%) |
| IIB           | 115 (61%) |
| Operative method, n (%) |       |
| PD            | 102 (54%) |
| PPPD          | 62 (33%)  |
| Other*        | 25 (13%)  |
| Tumor location, n (%) |     |
| Head or neck  | 132 (70%) |
| Uncinate process | 34 (18%) |
| Body          | 16 (8%)   |
| Tail          | 7 (4%)    |
| Resection margin, n (%) |       |
| Positive      | 40 (21%)  |
| Negative      | 149 (79%) |

IQR: Interquartile range; PD: pancreaticoduodenectomy; PPPD: pylorus-preserving pancreaticoduodenectomy; *subtotal and distal pancreatectomy, n=22; total pancreatectomy, n=3.
Table II. Univariate analysis of predictive factors for resection margin status.

| Characteristic       | Surgical margin status |
|----------------------|------------------------|
|                      | Negative (N=149)       | Positive (N=40) | p-Value |
| Age, years           | Mean±SD                | Mean±SD         |         |
|                      | 63.84±11.16            | 64.38±10.44     | 0.455   |
| Gender               | Male/female            | Male/female     |         |
|                      | 89/60                  | 23/17           | 0.799   |
| AST (U/I)            | Mean±SD                | Mean±SD         |         |
|                      | 79.13±88.51            | 84.92±105.57    | 0.732   |
| ALT (U/I)            | Mean±SD                | Mean±SD         |         |
|                      | 115.28±137.98          | 123.53±156.57   | 0.753   |
| Bilirubin (mg/dl)    | Total                  | Direct          |         |
|                      | 4.74±5.15              | 2.98±3.28       | 0.027   |
|                      |                       | 2.42±3.11       | 22 (65%) |
|                      |                       | 12 (35%)        | 12 (35%) |
| ALK-P (U/I)          | Mean±SD                | Mean±SD         |         |
|                      | 152±135.95             | 129±130.66      | 0.027   |
| Lipase (U/I)         | Mean±SD                | Mean±SD         |         |
|                      | 225.9±34.16            | 331.29±173.35   | 0.367   |
| Albumin (g/dl)       | Mean±SD                | Mean±SD         |         |
|                      | 3.81±0.64              | 3.77±0.57       | 0.729   |
| CEA (ng/ml)          | Mean±SD                | Mean±SD         |         |
|                      | 15.86±96.05            | 9.4±32.80       | 0.723   |
|                      | >5/≤5 ng/ml            | 35/95           | 0.366   |
| CA19-9 (U/ml)        | Mean±SD                | Mean±SD         |         |
|                      | 4151.29±3997.14        | 1755±1093.14    | 0.579   |
|                      | >246/≤246 U/ml         | 21/12           | 0.035   |
| Tumor size           | Mean±SD                | Mean±SD         |         |
|                      | 3.19±1.31              | 3.23±1.56       | 0.860   |
| Tumor size           | >2/≤2 cm               | 122/27          | 0.733   |
|                      | 18 (90%)               | 2 (10%)         | 0.273   |
|                      | 128 (77%)              | 38 (23%)        |         |
| Positive LN          | Mean±SD                | Mean±SD         |         |
|                      | 1.65±1.97              | 1.52±2.48       | 0.721   |
| N-Stage              | Mean±SD                | Mean±SD         |         |
|                      | 61 (79%)               | 16 (21%)        | 0.914   |
|                      | 88 (79%)               | 24 (21%)        |         |
| LNR                   | Mean±SD                | Mean±SD         |         |
|                      | 0.80 (80%)             | 15 (20%)        | 0.888   |
|                      | 54 (78%)               | 15 (22%)        |         |
|                      | 18 (75%)               | 6 (25%)         |         |
|                      | 16 (84%)               | 3 (16%)         |         |
| Histology            | Mean±SD                | Mean±SD         |         |
|                      | 3 (75%)                | 1 (25%)         | 0.233   |
|                      | 15 (94%)               | 1 (6%)          |         |
|                      | 35 (24%)               | 3 (12%)         |         |
| Mitotic count        | Mean±SD                | Mean±SD         |         |
|                      | 3 (100%)               | 0 (0%)          | 0.799   |
|                      | 18 (77%)               | 38 (23%)        |         |
| Vascular invasion    | Mean±SD                | Mean±SD         |         |
|                      | 38 (91%)               | 6 (31)          | 0.140   |
|                      | 61 (69%)               | 12 (25)         | 0.135   |
|                      | 115 (14)               | 33 (4)          | 1.000   |
| Tumor stage          | Mean±SD                | Mean±SD         |         |
|                      | 2 (100%)               | 0 (0%)          | 0.706   |
|                      | 13 (87%)               | 2 (13%)         |         |
| Operative method     | Mean±SD                | Mean±SD         |         |
|                      | 82 (80%)               | 20 (20%)        | 0.239   |
|                      | 40 (79%)               | 17 (27%)        |         |
|                      | 22 (88%)               | 3 (12%)         |         |
| Tumor location       | Mean±SD                | Mean±SD         |         |
|                      | 109 (83%)              | 23 (17%)        | 0.138   |
|                      | 22 (65%)               | 12 (35%)        | 12 (35%) |
|                      | 12 (75%)               | 4 (25%)         | 28 (18%) |
|                      | 6 (86%)                | 1 (14%)         |         |
|                      | 22 (65%)               | 12 (35%)        | 0.027   |
|                      | 127 (82%)              | 28 (18%)        |         |

AST: Aspartate aminotransferase; ALT: alanine transaminase; Bil: bilirubin; ALK-P: alkaline phosphatase; CEA: carcinoembryonic antigen; CA 19-9: Carbohydrate Antigen 19-9; LN: lymph node; LNR: lymph node raatio; PD: pancreaticoduodenectomy, classical type; PPPD: pylorus-preserving pancreatoduodenectomy; *total pancreatectomy.
Discussion
PDAC is a disease with a dismal outcome, and surgical resection is the only method for improving survival. In the seventh edition of the AJCC staging manual, PDAC of stages IA, IB, IIA and IIB is categorized as resectable. In contrast, stage III and stage IV PDAC are categorized as borderline resectable or unresectable. For most pathological diagnoses for malignancies, clearance of the resection margin is an index of surgical quality and an indicator of prognosis. In our study, we attempted to investigate the impact of margin status on overall survival.

From the perspective of surgical oncology, optimal margin clearance of solid tumors is the primary objective. However, positive margin status is sometimes inevitable. In our study, the rate of margin positivity was 21%. In previous reports, positive margin rates among PDAC patients undergoing resection with radical intent ranged from 14% to 60% (8). In our study, we found that high serum CA19-9 level and tumor location in the uncinate process were factors predictive of margin positivity. Furthermore, our analyses indicated that CA19-9 was an independent risk factor. Based on our receiver operating characteristics curve analysis, the optimal cutoff value of CA19-9 for prediction of positive surgical margins was 246 U/ml. CA19-9 has been reported to be a useful biochemical marker for diagnosing pancreatic cancer (9) and a predictor of overall survival for patients with resectable PDAC (10). Therefore, CA19-9 should be regarded as a predictive marker for positive surgical margins that has versatile clinical applications. Furthermore, our report found that the incidence of margin positivity was elevated for patients with tumors located in the uncinate process (Table II).

Our series included 34 patients (17.9%) with a tumor in an uncinate location. However, the incidence of surgical margin positivity was much higher in this group than among patients with non-uncinate lesions (35% versus 18%). Retroperitoneal soft-tissue margins were the most common location for positive surgical margins, accounting for 60% of our cases with such margins. This result was consistent with the corresponding percentages of 80% (11) and 73% (8) reported in prior studies that also suggested that the retroperitoneal soft tissue is the most common site of positive surgical margins. In addition, our results (Table III) also showed a trend that positive retroperitoneal soft-tissue margins were more common for those with tumors primarily located in the uncinate process than for other tumors (p=0.074).

For years, studies have attempted to elucidate factors that influence survival for patients with PDAC. Various risk factors, including preoperative biliary stent, CA19-9 level, blood transfusion, R0 resection, tumor size, absence of lymph node or distant metastases, and peri-neural infiltration, have been discussed (16). For a surgical oncologist, R0 resection may be the most important consideration. Certain studies have demonstrated that surgical margin affects survival (17-19), although this effect was not observed in other investigations (5, 11, 20, 21). One study even proposed that repeated resection for margin clearance did not improve outcome (22). One possible reason for these inconsistent research results is lack of standardization of margin definitions (23, 24); another potential reason is the evolution of more efficient adjuvant chemotherapy regimens. In our study, adjuvant chemotherapy regimens were not unified but were instead chosen based on physicians’ preferences and patient tolerance. All of these factors may have influenced the results of individual studies.

For patients with cancer, different pathological stages can indicate different survival statuses; staging systems exist for this reason. The main purpose of our work was to evaluate the impact of positive signal margins on survival. Therefore, in our study, it is reasonable to conduct subgroup analysis based on cancer stage, using multivariate analysis to eliminate the confounding effects of other factors. For patients with stage IIA PDAC, surgical margin, tumor size, CA19-9 level,
Lai et al: Risk Factors for the Survival Impact of Positive Margins in PDAC

Figure 2. Survival curves for patients with negative and positive resection margins.

Table IV. Cox’s proportional hazards analysis in patients with stage IIA disease.

| Factor                        | Hazard ratio (95% CI) | p-Value |
|-------------------------------|-----------------------|---------|
| Age Per year increase         | 1.004 (0.958-1.052)   | 0.869   |
| Gender M vs. F                | 1.589 (0.675-3.742)   | 0.289   |
| Tumor size Per cm increase    | 0.506 (0.230-1.113)   | 0.090   |
| Tumor location Uncinate vs. non-uncinate | 0.883 (0.287-2.711) | 0.827 |
| CA19-9 Per U/ml increase     | 1.000 (1.000-1.000)   | 0.008   |
| Resection margin Positive vs. negative | 4.839 (1.700-13.772) | 0.003 |
| Chemotherapy No vs. yes       | 1.471 (0.609-3.557)   | 0.391   |
| LNR Per unit increase         | 0.595 (0.080-4.431)   | 0.613   |
| Histology Moderately vs. well-differentiated | 0.018 (0.001-0.215) | 0.002 |
| Poorly vs. well-differentiated | 0.027 (0.003-0.261)  | 0.002   |
| Mitotic count Intermediate vs. low | 0.000 (0.000--)   | 0.978   |
| Moderate vs. low              | 0.785 (0.304-2.032)   | 0.618   |
| High vs. low                  | 0.091 (0.007-1.109)   | 0.060   |
| Vascular invasion Yes vs. no  | 1.163 (0.526-2.570)   | 0.709   |
| Lymphatic invasion Yes vs. no | 0.832 (0.352-1.965)   | 0.675   |
| Peri-neural invasion Yes vs. no | 0.772 (0.170-3.512) | 0.112   |

CA 19-9: Carbohydrate antigen 19-9; LNR: lymph node ratio.

Table V. Cox’s proportional hazards analysis in patients with stage IIB disease.

| Factor                        | Hazard ratio (95% CI) | p-Value |
|-------------------------------|-----------------------|---------|
| Age Per year increase         | 0.984 (0.961-1.007)   | 0.169   |
| Gender M vs. F                | 0.723 (0.413-1.265)   | 0.255   |
| Tumor size Per cm increase    | 1.146 (0.850-1.545)   | 0.372   |
| Tumor location Uncinate/non-uncinate | 0.945 (0.500-1.784) | 0.860 |
| CA19-9 Per U/ml increase     | 1.000 (1.000-1.000)   | 0.001   |
| Resection margin Positive vs. negative | 0.696 (0.345-1.406) | 0.313 |
| Chemotherapy No vs. yes       | 1.401 (0.808-2.428)   | 0.230   |
| LNR Per unit increase         | 4.475 (0.849-23.580)  | 0.077   |
| Histology Moderately vs. well-differentiated | 2.047 (0.769-5.446) | 0.152 |
| Poorly vs. well-differentiated | 2.322 (0.616-8.756)  | 0.214   |
| Mitotic count Intermediate vs. low | 0.460 (0.097-2.172) | 0.327 |
| Moderate vs. low              | 1.394 (0.786-2.471)   | 0.256   |
| High vs. low                  | 0.710 (0.232-2.172)   | 0.548   |
| Vascular invasion Yes vs. no  | 1.805 (0.988-3.297)   | 0.055   |
| Lymphatic invasion Yes vs. no | 0.979 (0.532-1.801)   | 0.946   |
| Peri-neural invasion Yes vs. no | 0.622 (0.242-1.597)  | 0.323   |

CA 19-9: Carbohydrate antigen 19-9; LNR: lymph node ratio.
and histology were all independent factors for survival. For patients with stage IIB PDAC, no independent factors for survival were identified. Because pancreatic cancer has been recognized as a systemic disease (25, 26), different disease stages may reflect different extents of involvement. This phenomenon may explain our observations. For stage IIA disease, a positive surgical margin was an independent factor for survival; for stage IIB disease, no local factors for survival were identified. Stage IIA PDAC should be regarded as a more localized condition for which the surgical margin affects survival. Pancreatic surgeons should attempt to perform radical surgery for PDAC by stage IIA in order to achieve favorable survival outcomes.

Our study had several limitations. The study period was almost 10 years. Treatment of PDAC has improved during this period with respect to both surgical techniques and systemic treatment. This evolution in treatment may have produced detectable or undetectable survival benefits. In addition, the definition of a positive surgical margin and the standard procedure for pathological examination of the resection margin may have incorporated additional biases into our study. These potential biases render it difficult to compare different studies on this topic.

Conclusion

In our study, we found that the retroperitoneal soft tissue is the most common location for positive margins among patients with PDAC who underwent surgery. In addition, positive margins were more common for tumors located in the uncinate process than for other tumors. With respect to survival impact, positive surgical margins had a negative impact on survival of patients with stage II PDAC who underwent surgery.

References

1 Gong Z, Holly EA and Bracci PM: Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol 174(12): 1373-1381, 2011.
2 Shaib WL, Ip A, Cardona K, Alesse OB, Maithel SK, Kooby D, Landry J and El-Rayes BF: Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer. Oncologist 21(2): 178-187, 2016.
3 Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB and Bauer TW: Preoperative capcitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 18(3): 619-627, 2011.
4 Cameron JL, Riall TS, Coleman J and Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann Surg 244(1): 10-15, 2006.
5 Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthay J-N, Abdalla EK, Lee JE, Pisters PWT and Evans DB: Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1): 52-60, 2007.
6 Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD and Berry DP: Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J Pancreas 9(2): 99-132, 2008.
7 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010.
8 Lavu H, Mascaro AA, Grenda DR, Sauter PK, Leiby BE, Croker SP, Witkiewicz A, Berger AC, Rosato EL, Kennedy EP and Yeo CJ: Margin positive pancreaticoduodenectomy is superior to palliative bypass in locally advanced pancreatic ductal adenocarcinoma. J Gastrointest Surg 13(11): 1937-1946, 2009.
9 Goonetilleke KS and Sirivardena AK: Systematic review of carbohydrate antigen (ca 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3): 266-270, 2007.
10 Dong Q, Yang X-H, Zhang Y, Jing W, Zheng L-Q, Liu Y-P and Qu X-J: Elevated serum ca19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: A pilot study. World J Surg Oncol 12: 171, 2014.
11 Westgaard A, Tafjord S, Farstad IN, Cvanarcrova M, Eide TJ, Mathisen O, Clausen OP and Gladhaug IP: Resectable adenocarcinomas in the pancreatic head: The retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 8: 5, 2008.
12 Eom BW, Joo J, Kim YW, Park B, Park JY, Yoon HM, Lee JH and Ryu KW: Is there any role of additional retropancreatic lymph node dissection on d2 gastrectomy for advanced gastric cancer? Ann Surg Oncol 20(8): 2669-2675, 2013.
13 Adham M, Jaeck D, Le Borgne J, Oussoultzoglou E, Chenard-Neu MP, Mossier JF, Scoazec JY, Mornex F and Partensky C: Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: A series of 30 patients collected from 3 institutions. Pancreas 37(4): 352-357, 2008.
14 Conlon KC, Klimstra DS and Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 222(3): 273-279, 1996.
15 Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6): 567-579, 2000.
16 Dusch N, Weiss C, Strobel P, Kienle P, Post S and Niedergethmann M: Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg 18(4): 674-681, 2014.
17 Han S-S, Jang J-Y, Kim S-W, Kim W-H, Lee KU and Park Y-H: Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32: 271-275, 2006.
18 Elberhim H, Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, Bond-Smith G, Bramhall S, Coldham C, Hammond J, Hutchins R, Imber C, Preziosi G, Saleh A, Silva M, Simpson J, Spoletini G, Stell D, Terrace J, White S, Wigmore S and Fusai G: Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection For Pancreatic Cancer Study Group. Eur J Surg Oncol 41(11): 1500-1507, 2015.
19 Benassai G, Quarto G, Perrotta S, Furino E, Benassai GL, Amato B, Bianco T, De Palma G and Forestieri P: Long-term survival after curative resection for pancreatic ductal adenocarcinoma—surgical treatment. Int J Surg Suppl 1: S1-3, 2015.

20 Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW and European Study Group for Pancreatic Cancer: Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection. JAMA 304 (10): 1073-1081, 2010.

21 Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B and Gallinger S: Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg 198(5): 722-731, 2004.

22 Petrucciani N, Nigri G, Debs T, Giannini G, Sborlini E, Antolino L, Aurello P, D’Angelo F, Gugenheim J and Ramacciato G: Frozen section analysis of the pancreatic margin during pancreati-coduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology 16(6): 1037-1043, 2016.

23 Åkerberg D, Ansari D and Andersson R: Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol 22(28): 6424-6433, 2016.

24 Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ, Samra JS, Merrett ND, Richardson AJ and Barbour AP: Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 102(12): 1459-1472, 2015.

25 Kang MJ, Jang JY and Kim SW: Surgical resection of pancreatic head cancer: What is the optimal extent of surgery? Cancer Lett 382(2): 259-265, 2016.

26 Sohal DP, Walsh RM, Ramanathan RK and Khorana AA: Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy. J Natl Cancer Inst 106(3): dju011, 2014.

Received June 9, 2018
Revised July 5, 2018
Accepted July 16, 2018